A quarterly stock award gives director Fox 308 shares of Edgewise Therapeutics (EWTX).
Edgewise Therapeutics director Jonathan C. Fox acquired 308 shares of common stock through restricted stock units on October 1, 2026, as a Quarterly Retainer Award. Following this transaction, his direct holdings increased to 25,141 shares. This insider trade is noted as neutral in sentiment and relates to the company's Outside Directors Compensation Policy.
(EWTX) Risk Channels and Responsive Allocation
This article from Stock Traders Daily analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting weak near and mid-term sentiment despite a long-term positive outlook. The analysis provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis showing support and resistance levels. The report emphasizes elevated downside risk due to a lack of additional long-term support signals.
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
Oppenheimer suggests that Edgewise Therapeutics (EWTX) could gain a significant advantage from the distinctive drug profile of its compound, EDG-7500. The article is very short and implies that a premium subscription is required to read the full details of this analysis.
Edgewise Therapeutics Down Over 9%, on Pace for Largest Percent Decrease Since December 2025 -- Data Talk
Edgewise Therapeutics (EWTX) shares are down over 9% and are on track for their largest percentage decrease since December 2025. The stock is currently trading at $13.78, reflecting a 9.39% decline from its previous close. This movement comes during a period where the Nasdaq is also seeing declines.
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright has reiterated its Buy rating for Edgewise Therapeutics (EWTX.US), maintaining a target price of $57. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Edgewise unveils mechanism of action for heart drug EDG-7500
Edgewise Therapeutics announced preclinical data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, showing improved cardiac relaxation without affecting systolic function in models and early clinical observations. The company plans to initiate a Phase 3 trial in Q4 2026 for the investigational oral drug, which is designed to address excessive contraction and thickening of the heart's left ventricular wall.
Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 - Slideshow (NASDAQ:EWTX) 2026-09-22
Edgewise Therapeutics, Inc. (EWTX) has published a slide deck discussing the differentiated mechanism of action of its cardiac sarcomere modulator, EDG-7500. This slideshow provides insight into the company's research and development in this area. The information was released on September 22, 2026.
EWTX: EDG-7500 improves cardiac relaxation in HCM and advances to Phase 3 after positive Phase 2 data
Edgewise Therapeutics' (EWTX) EDG-7500, a cardiac sarcomere modulator, has shown positive results in improving cardiac relaxation and safety in both preclinical and Phase 2 studies for hypertrophic cardiomyopathy. Following these favorable outcomes, the company plans to initiate a Phase 3 trial for EDG-7500 in late 2026. This development suggests a significant step forward in the treatment of HCM.
Edgewise screened more than 7,000 candidates for a heart treatment. EDG-7500 improved relaxation in early tests.
Edgewise Therapeutics (EWTX) announced details regarding its cardiac sarcomere modulator, EDG-7500, a first-in-class treatment targeting the regulatory light chain (RLC) for symptomatic heart failure. Preclinical studies and early clinical observations showed EDG-7500 improves cardiac relaxation while maintaining systolic function. The company screened over 7,000 RLC candidates to identify this molecule, and is preparing to initiate a Phase 3 trial in Q4 2026.
Edgewise Therapeutics unveils EDG-7500, a new drug improving heart relaxation in hypertrophic cardiomyopathy patients.
Edgewise Therapeutics announced promising preclinical and early clinical results for EDG-7500, a novel cardiac drug designed to improve heart relaxation in patients with symptomatic hypertrophic cardiomyopathy (HCM) without impairing contraction. The company plans to initiate a Phase 3 trial in late 2026 following successful Phase 2 trial outcomes. This first-in-class treatment targets the Regulatory Light Chain and aims to address the genetic heart disease.
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics announced the differentiated mechanism of action (MoA) of its cardiac sarcomere modulator EDG-7500, which targets the Regulatory Light Chain (RLC). Preclinical models show EDG-7500 improves cardiac relaxation while preserving systolic function and cardiac reserve, with early clinical observations in hypertrophic cardiomyopathy (HCM) patients supporting these findings. The company is hosting a webcast to discuss these data and expects to initiate a Phase 3 trial in Q4 2026 for EDG-7500, an investigational oral therapy for HCM.
HC Wainwright & Co. maintains Buy rating on Edgewise Therapeutics, $57 price target
HC Wainwright & Co. has reiterated its Buy rating for Edgewise Therapeutics (EWTX), setting a price target of $57.00, which suggests a 25.8% upside from the Sep 18 closing price. The key factors influencing this positive outlook are strong Phase 2 clinical data for EDG-7500 in hypertrophic cardiomyopathy and enhanced financial stability due to a $1.55 billion upfront payment from the Servier transaction, reducing financing risks.
Biotech Options Buzz: UTHR, NMRA, EWTX
The article highlights unusual options activity in biotech stocks United Therapeutics (UTHR), Neumora Therapeutics (NMRA), and Edgewise Therapeutics (EWTX). UTHR saw balanced call and put activity after its CEO's family trust sold shares. NMRA experienced high put volume as it hit 52-week lows, while EWTX saw heavy call volume despite a slight dip from its all-time high.
Edgewise Therapeutics stock hits all-time high at 48.41 USD By Investing.com
Edgewise Therapeutics Inc. stock has reached an all-time high of $48.41, marking a significant 1-year surge of 208.11%. This milestone follows the company's sale of its muscular dystrophy business to Servier for up to $2.65 billion and positive analyst coverage from Oppenheimer, Guggenheim, and RBC Capital. Despite the rapid growth, InvestingPro's Fair Value analysis suggests the stock may be overvalued.
Edgewise Therapeutics stock hits all-time high at 48.41 USD
Edgewise Therapeutics Inc. (EWTX) stock reached an all-time high of $48.41, reflecting a 208.11% one-year change and a 227% actual return. This surge follows the company's sale of its muscular dystrophy business for up to $2.65 billion and positive analyst coverage with raised price targets from Oppenheimer, Guggenheim, and RBC Capital. InvestingPro data suggests the stock might be overvalued but notes its proximity to a 52-week high, underscoring strong market interest.
CIRRUS-HCM: EDG-7500 Improves LVOT, NYHA Class in oHCM and nHCM
The CIRRUS-HCM trial demonstrated that EDG-7500, a novel cardiac sarcomere modulator, significantly improved left ventricular outflow tract (LVOT) gradients and New York Heart Association (NYHA) functional class in patients with both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) over 12 weeks. The treatment maintained systolic function without clinically meaningful changes in left ventricular ejection fraction (LVEF) and was well-tolerated. These positive Phase 2 results support the drug's continued development and readiness for Phase 3 trials by late 2026.
The Technical Signals Behind (EWTX) That Institutions Follow
This article analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX) based on AI-generated technical signals. It highlights weak near-term sentiment potentially challenging long-term strength, with resistance being tested. The analysis provides specific risk-reward setups, institutional trading strategies for various risk profiles, and a multi-timeframe signal analysis, suggesting choppy conditions due to divergent sentiment.
Edgewise Therapeutics presents positive Phase 2 trial data for EDG-7500 in hypertrophic cardiomyopathy at ESC Congress
Edgewise Therapeutics announced positive top-line results from its 12-week Phase 2 CIRRUS-HCM trial for EDG-7500, a new oral drug for hypertrophic cardiomyopathy (HCM). The data, to be presented at the European Society of Cardiology Congress in August 2026, suggest EDG-7500 could improve heart relaxation and function in symptomatic HCM patients. This trial is part of a broader study addressing the unmet need in treating this genetic heart disease.
Edgewise's 12-week heart treatment study gets a late-breaking slot in Munich
Edgewise Therapeutics announced that its CIRRUS-HCM Phase 2 trial data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy, has been selected for a late-breaking science presentation at the ESC Congress 2026 in Munich. The presentation will feature 12-week top-line data from the trial, focusing on both obstructive and nonobstructive forms of the condition. This announcement highlights the company's focus on cardiovascular diseases and the potential of EDG-7500 as a novel therapeutic approach.
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Edgewise Therapeutics announced that its CIRRUS-HCM abstract has been selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress in August 2026. The presentation will highlight positive top-line data from the 12-week Phase 2 CIRRUS-HCM trial, evaluating EDG-7500, a novel cardiac sarcomere modulator, for the safety and efficacy in treating obstructive and nonobstructive hypertrophic cardiomyopathy (HCM). HCM is a common genetic heart disease causing significant functional limitations and is associated with heart failure, abnormal heart rhythms, and sudden cardiac death.
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Edgewise Therapeutics (NASDAQ:EWTX) Stock
JPMorgan Chase & Co. has increased its price target for Edgewise Therapeutics (NASDAQ:EWTX) to $60 from $53, maintaining an "overweight" rating and suggesting a 37.61% upside. Despite this positive analyst sentiment and a "Moderate Buy" consensus rating, the company recently missed quarterly EPS estimates, and insiders have sold a significant number of shares. Hedge funds, however, have either increased or initiated new positions in the stock.
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?
Edgewise Therapeutics (EWTX) reported wider net losses in Q2 2026 and the first half of 2026, highlighting increased spending relative to its revenue base. Despite this, the stock rose 6.6%, suggesting investors are focused on future clinical and regulatory catalysts for its late-stage pipeline. The widening losses emphasize the company's reliance on external capital and the importance of future funding rounds.
Edgewise Therapeutics (EWTX) Is Up 6.6% After Wider Q2 Losses Highlight Rising Spend - Has The Bull Case Changed?
Edgewise Therapeutics (EWTX) reported wider net losses in Q2 2026 and the first half of 2026, totaling US$57.33 million and US$106.34 million respectively, indicating increased spending. Despite this, the stock rose 6.6%, suggesting investors remain focused on the company's late-stage pipeline and upcoming clinical and regulatory milestones rather than near-term losses. However, the widening losses underscore the importance of future capital raises and present a risk due to the company's reliance on external funding.
Edgewise Therapeutics (EWTX) gives CSO 65K options at $43.56
Edgewise Therapeutics (EWTX) reported that its Chief Scientific Officer, Alan J. Russell, was granted 65,000 stock options on August 12, 2026. An amended filing corrected the exercise price to $43.56 per share, reflecting the fair market value on the grant date, with an expiration date of August 12, 2036. The options will vest in monthly installments over approximately four years, contingent on Russell's continued service.
Edgewise (NASDAQ: EWTX) CBO gets 100K options vesting from 2026
Edgewise Therapeutics, Inc. reported that its Chief Business Officer, Behrad Derakhshan, was granted 100,000 stock options. An amendment corrected the exercise price to $43.56 per share, reflecting the fair market value on the grant date. These options will vest in monthly installments over 48 months starting September 12, 2026, provided Derakhshan continues his service.
Edgewise Therapeutics (EWTX) sets GC option price at $43.56
Edgewise Therapeutics reported that its General Counsel, John R. Moore, was granted a stock option for 65,000 shares of common stock. The exercise price was corrected to $43.56 per share, reflecting the fair market value on the grant date, and the options will vest monthly starting September 12, 2026, with an expiration date of August 12, 2036. This amended filing corrects a previous clerical error regarding the exercise price.
69,441 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Persistent Asset Partners Ltd
Persistent Asset Partners Ltd recently acquired 69,441 shares of Edgewise Therapeutics (EWTX) for approximately $2.82 million, making it their 23rd largest holding. Despite some insider selling to cover tax obligations, analysts maintain a "Moderate Buy" rating with an average price target of $49.08. Edgewise Therapeutics, a clinical-stage biopharmaceutical company, reported a quarterly loss that missed estimates.
44,466 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by GSA Capital Partners LLP
GSA Capital Partners LLP recently acquired 44,466 shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) valued at approximately $1.81 million. Other institutional investors also increased their holdings, while company insiders sold shares primarily to cover tax obligations related to vested equity awards, maintaining significant ownership. Analysts generally hold a "Moderate Buy" rating for EWTX, with an average price target of $49.08, despite the company reporting a quarterly EPS miss.
Edgewise Therapeutics (EWTX) Reports Wider Losses On A Valuation That Still Looks Rich
Edgewise Therapeutics (EWTX) reported wider net losses in Q2 2026, yet its shares have seen significant price appreciation year-to-date. The company's Price-to-Book ratio of 10.7x is significantly higher than the US Pharmaceuticals sector average, indicating investors are pricing in strong future potential despite current unprofitability. While the P/B is below its direct peer group, the valuation suggests high expectations based on its pipeline, coupled with inherent risks like ongoing losses and reliance on clinical trial success.
Edgewise Therapeutics CSO Alan Russell sells $258k in stock
Edgewise Therapeutics CSO Alan Russell sold shares worth $258,042 to cover tax obligations related to RSU vesting. Despite the "sell-to-cover" transaction, he received new RSUs and stock options, increasing his potential holdings. This follows the company's recent sale of its muscular dystrophy business for up to $2.65 billion and several positive analyst outlooks, with the stock up 212% over the past year.
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock
Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock options. These transactions follow a significant strategic move by Edgewise Therapeutics, which completed the sale of its muscular dystrophy business for a potential $2.65 billion, leading to positive analyst ratings and raised price targets.
Edgewise Therapeutics CMO Joanne Donovan sells $412,703 in stock
Joanne M. Donovan, CMO of Edgewise Therapeutics, sold 9,441 shares totaling $412,703 in August 2026, with a portion covering tax obligations from RSU vesting and the remainder under a Rule 10b5-1 plan. These sales followed her acquisition of shares from RSU vesting and new grants of RSUs and stock options. The company recently sold its muscular dystrophy business to Servier for up to $2.65 billion and has received positive analyst ratings.
Edgewise Therapeutics CSO Alan Russell sells $258k in stock
Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, sold 5,901 shares of company stock for $258,042, primarily to cover tax obligations from RSU vesting. Following the sale, he still holds 31,466 shares directly, along with additional RSUs and stock options. This transaction follows the company's recent sale of its muscular dystrophy business to Servier for up to $2.65 billion and updated positive analyst ratings.
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock
Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock, primarily to cover tax obligations from vested Restricted Stock Units. The sales involved 17,971 shares at prices between $43.26 and $44.33, while Koch also acquired and was granted new RSUs and stock options. These transactions follow Edgewise Therapeutics' recent sale of its muscular dystrophy business for up to $2.65 billion, which has led to positive analyst sentiment and updated price targets.
Edgewise Therapeutics (EWTX) grants 50,000 RSUs and 100,000 options to CBO
Edgewise Therapeutics reported that its Chief Business Officer, Derakhshan Behrad, received equity awards comprising 50,000 Restricted Stock Units (RSUs) and a stock option for 100,000 shares. Behrad also had 5,781 and 7,500 RSUs convert into common stock on August 12, 2026, and subsequently sold 5,100 shares to cover tax withholding obligations through a non-discretionary sell-to-cover arrangement. The new RSUs vest in four annual installments starting August 12, 2027, and the stock option vests monthly over 48 months from September 12, 2026.
Edgewise Therapeutics (NASDAQ:EWTX) General Counsel Sells $219,801.12 in Stock
Edgewise Therapeutics General Counsel John Moore sold 5,016 shares of EWTX stock worth $219,801.12 to cover tax withholding obligations from vested equity awards, reducing his direct ownership by 22.08%. The company's stock is trading near its 52-week high, and despite missing recent earnings expectations, analysts maintain a "Moderate Buy" consensus rating with an average price target of $49.08.
RA Capital’s 7.8% Edgewise Therapeutics (EWTX) stake totals 8.39M shares
RA Capital Management, L.P. and its affiliated parties have reported a 7.8% stake in Edgewise Therapeutics, Inc. (EWTX), totaling 8,392,730 shares of common stock. This ownership is held by RA Capital Healthcare Fund, L.P., with RA Capital having shared voting and dispositive power over these shares. The filing indicates a neutral impact and sentiment regarding this amended passive investment disclosure.
Edgewise Therapeutics (EWTX) CSO gets 97,500-share equity awards, sells shares for taxes
Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, reported equity transactions on August 12, 2026, which included exercising Restricted Stock Units and selling 5,901 shares to cover tax withholding obligations. Additionally, Russell received new equity awards comprising 32,500 RSUs and a stock option for 65,000 shares, with specified vesting schedules. These transactions highlight routine insider compensation activities at the company.
Edgewise Therapeutics (EWTX) grants CFO 24,375 RSUs and 48,750-share option
Edgewise Therapeutics (EWTX) has granted its CFO, Michael Nofi, 24,375 Restricted Stock Units (RSUs) and an option for 48,750 shares of common stock. The RSUs vest in four equal annual installments starting August 12, 2027, and the stock options vest monthly over 48 months beginning September 12, 2026, both contingent on his continued service. These equity awards aim to align the CFO's compensation with the company's long-term performance and retain his services.
Edgewise Therapeutics (NASDAQ:EWTX) CMO Sells 6,522 Shares
Edgewise Therapeutics CMO Joanne Donovan recently sold 6,522 shares of EWTX stock for $285,989.70 to cover tax withholding obligations on vested equity awards, reducing her holdings by 36.1%. Despite this insider sale and a quarterly earnings miss, the company's shares rose 2.3%, and analysts maintain a "Moderate Buy" rating with a consensus price target of $49.08. Major institutional investors, including BlackRock Inc., have also increased their positions in the company.
Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares
Edgewise Therapeutics (NASDAQ:EWTX) insider Alan Russell sold 5,901 shares of the company's stock on August 12th, 2026, totaling approximately $258,051. This sale was conducted to cover tax withholding obligations related to vested equity awards. Despite this insider selling, analysts maintain a "Moderate Buy" consensus rating for EWTX, with an average price target of $49.08, and major institutional investors have recently increased their holdings.
Bank of America Corp DE Decreases Position in Edgewise Therapeutics, Inc. $EWTX
Bank of America Corp DE reduced its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 10% in the first quarter, selling 147,437 shares but still retaining 1.33 million shares valued at $41.8 million. Despite this reduction, other institutional investors like Janus Henderson and UBS Group increased their holdings. Edgewise Therapeutics shares opened at $43.18, and analysts maintain a "Moderate Buy" rating with a $49.08 average price target, even though the company missed its latest quarterly EPS estimate.
Edgewise Therapeutics, Inc. SEC Filing (Aug 13, 2026)
Edgewise Therapeutics, Inc. (EWTX) filed a Form 144 with the SEC on August 13, 2026, indicating a proposed sale of securities. The filing details the sale of 2,919 shares of common stock with an aggregate market value of $127,151.64 by an individual who acquired these shares as Restricted Stock Units on August 12, 2025. This neutral filing, processed by Rhea-AI, provides transparency into insider stock sales.
EWTX Maintains Neutral Rating - Price Target Raised to $36.00 by Goldman Sachs
Goldman Sachs has maintained a Neutral rating on Edgewise Therapeutics (EWTX) but increased its price target from $32.00 to $36.00. Despite the raised price target, the company's GF Score™ of 28/100, indicating financial challenges, and significant insider selling, suggest a cautious approach for investors. Edgewise Therapeutics focuses on developing treatments for muscular dystrophies and cardiac conditions, but profitability remains a concern.
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by California State Teachers Retirement System
The California State Teachers Retirement System increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 45.7% in the first quarter, acquiring an additional 23,027 shares and bringing its total holdings to 73,419 shares valued at approximately $2.3 million. Despite the company missing its latest earnings estimate and an insider selling a significant number of shares, analysts maintain a "Moderate Buy" rating with a target price of $48.75. Edgewise Therapeutics, a clinical-stage biopharmaceutical company, opened at $44.58 per share, up 2.4%, with a market capitalization of $4.84 billion.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages
Edgewise Therapeutics (NASDAQ:EWTX) has received a "Moderate Buy" consensus rating from eleven research firms, with an average 12-month price target of $48.75. The company recently reported a quarterly loss of $0.53 per share, missing consensus estimates, and insider Alan J. Russell sold a significant portion of his shares. The stock has seen various analyst price target adjustments, and institutional investors have been modifying their holdings.
Edgewise Therapeutics stock hits all-time high at 43.96 USD
Edgewise Therapeutics (EWTX) stock reached an all-time high of $43.96, currently trading at $44.17 with a market capitalization of $4.66 billion, reflecting a 231% increase over the past year. Despite this surge, InvestingPro data suggests the stock may be overvalued relative to its Fair Value. Recent analyst updates from RBC Capital, Goldman Sachs, Truist Securities, Leerink, and Guggenheim have set price targets ranging from $32 to $59, citing positive clinical trial results for EDG-7500 and the planned sale of its muscular dystrophy business unit.
Edgewise Therapeutics, Inc. (EWTX) stock price, news, quote and history
This page provides a comprehensive overview of Edgewise Therapeutics, Inc. (EWTX), including its current stock price, financial summary, historical data, and recent news. The company is a biopharmaceutical firm focused on developing therapies for muscle disorders, with lead product candidates like sevasemten for muscular dystrophy and EDG-7500 for hypertrophic cardiomyopathy. Recent news highlights include Q2 2026 financial results, the sale of its sevasemten muscular dystrophy business for up to $2.65 billion, and positive Phase 2 trial data for EDG-7500.
Edgewise Therapeutics, Inc. Stock 12‑Month Price Target Raised to $50.46, Implies 12% Upside
Analysts have raised the average 12-month price target for Edgewise Therapeutics, Inc. (EWTX) stock to $50.46, up from $49.92, suggesting a 12% potential upside based on the Aug. 5 closing price. The consensus rating from 13 covering analysts remains a "Buy," with 11 Buy ratings and 2 Holds.
Edgewise Therapeutics 2Q 2026: Net loss $57.3M, EPS ($0.53) — 10-Q Summary
Edgewise Therapeutics reported a net loss of $57.3M, or $0.53 per diluted share, for Q2 2026, an increase from $36.1M in the prior year. The company is strategically shifting its focus to its cardiovascular pipeline after selling its muscular dystrophy asset, sevasemten, to Servier for $1.55B, which significantly boosted its liquidity. Edgewise plans to initiate Phase 3 for EDG-7500 in Q4 2026 and Phase 2 for EDG-15400 in H2 2026.
